Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | LDHB | P07195 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30173709 | 1.00 | KDM4E (0.46) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL7771087 | 0.92 | TSHR (0.52) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL7771088 | 0.92 | TSHR (0.52) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL1234795 | 0.85 | TSHR (0.65) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL28938285 | 0.85 | TSHR (0.65) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL4115859 | 0.85 | TSHR (0.65) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL30461050 | 0.85 | TSHR (0.65) | KDM4ETSHRCPB1ABATLDHA | |
| SCHEMBL15662540 | 0.82 | POLB (0.31) | KDM4ETSHRPOLB | |
| SCHEMBL29871199 | 0.82 | POLB (0.31) | KDM4ETSHRPOLB | |
| SCHEMBL24180793 | 0.81 | KDM4E (0.43) | KDM4ETSHRCPB1ABATGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023156629-A1 | STEALTH-STABILIZED LIPO-POLYAMINO ACIDS | POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) | 2023-08-24 | — | — | WO | disclosed |
| US-9694085-B2 | Targeted therapeutic nanoparticles | NANODERM SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160106852-A1 | TARGETED THERAPEUTIC NANOPARTICLES | NANODERM SCIENCES, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-8470776-B2 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-1900742-A1 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AEterna Zentaris GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028934-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106852-A1 | TARGETED THERAPEUTIC NANOPARTICLES | CD44, PHOSPHO1, CD47 | KDM4E 4729/4885TSHR 2364/4885CPB1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.